Shares of Health Care sector company Repligen moved 0.5% today, and are now trading at a price of $152.34. The Mid-Cap stock's daily volume was 245,439 compared to its average volume of 913,573. The S&P 500 index returned a 0.0% performance.
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company is based in Waltham and has 1,778 full time employees. Its market capitalization is $8,570,144,256.
17 analysts are following Repligen and have set target prices ranging from $160.0 to $220.0 per share. On average, they have given the company a rating of buy. At today's prices, RGEN is trading -18.59% away from its average analyst target price of $187.12 per share.
Over the last year, RGEN's share price has increased by 11.1%, which represents a difference of -7.4% when compared to the S&P 500. The stock's 52 week high is $182.52 per share whereas its 52 week low is $102.97. With average free cash flows of $75.91 Million that have been growing at an average rate of 27.5% over the last 5 years, Repligen is in a position to continue its strong stock performance trend.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 175,394 | 25,677 | 149,717 | 92.7 |
| 2023 | 113,918 | 36,222 | 77,696 | -10.95 |
| 2022 | 172,083 | 84,834 | 87,249 | 68.02 |
| 2021 | 119,016 | 67,089 | 51,927 | 29.27 |
| 2020 | 62,625 | 22,455 | 40,170 | -17.54 |
| 2019 | 67,216 | 18,504 | 48,712 |
